Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 286 AL 300

The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis

Cheng H, Shang Y, Jiang L, Shi TL, Wang L.

Int J Neurosci. 2016;126(4):299-307. doi: 10.3109/00207454.2015.1015722. Epub 2015 May 22.

Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer's Drug Discovery

Bu XL, Rao PPN, Wang YJ.

Mol Neurobiol. 2016 Aug;53(6):3565-3575. doi: 10.1007/s12035-015-9301-4. Epub 2015 Jun 23.

Efficacy of Ginkgo biloba extract EGb 761(®) in dementia with behavioural and psychological symptoms: A systematic review

von Gunten A, Schlaefke S, Überla K.

World J Biol Psychiatry. 2016 Dec;17(8):622-633. doi: 10.3109/15622975.2015.1066513. Epub 2015 Jul 30.

Hybrids: a new paradigm to treat Alzheimer's disease

Singh M, Kaur M, Chadha N, Silakari O.

Mol Divers. 2016 Feb;20(1):271-97. doi: 10.1007/s11030-015-9628-9. Epub 2015 Sep 2.

Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Br J Pharmacol. 2016 Jul;173(13):2080-94. doi: 10.1111/bph.13318. Epub 2015 Dec 1.

Pressure ulcers induced by drug administration: A new concept and report of four cases in elderly patients

Mizokami F, Takahashi Y, Hasegawa K, Hattori H, Nishihara K, Endo H, Furuta K, Isogai Z.

J Dermatol. 2016 Apr;43(4):436-8. doi: 10.1111/1346-8138.13093. Epub 2015 Sep 14.

Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease

Isaacson RS, Ferris S, Velting DM, Meng X.

Am J Alzheimers Dis Other Demen. 2016 May;31(3):270-7. doi: 10.1177/1533317515603687. Epub 2015 Sep 14.

Why therapies for Alzheimer's disease do not work: Do we have consensus over the path to follow?

Amtul Z.

Ageing Res Rev. 2016 Jan;25:70-84. doi: 10.1016/j.arr.2015.09.003. Epub 2015 Sep 12.

Alzheimer's disease drug development based on Computer-Aided Drug Design

Zeng H, Wu X.

Eur J Med Chem. 2016 Oct 4;121:851-863. doi: 10.1016/j.ejmech.2015.08.039. Epub 2015 Sep 3.

Caregiver burden in atypical dementias: comparing frontotemporal dementia, Creutzfeldt-Jakob disease, and Alzheimer's disease

Uflacker A, Edmondson MC, Onyike CU, Appleby BS.

Int Psychogeriatr. 2016 Feb;28(2):269-73. doi: 10.1017/S1041610215001647. Epub 2015 Oct 5.

Myeloid cell-based therapies in neurological disorders: How far have we come?

Böttcher C, Priller J.

Biochim Biophys Acta. 2016 Mar;1862(3):323-8. doi: 10.1016/j.bbadis.2015.10.003. Epub 2015 Oct 8.

Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer's Disease

Sheng R, Tang L, Jiang L, Hong L, Shi Y, Zhou N, Hu Y.

ACS Chem Neurosci. 2016 Jan 20;7(1):69-81. doi: 10.1021/acschemneuro.5b00224. Epub 2015 Oct 28.

A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease

Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL.

J Am Med Dir Assoc. 2016 Feb;17(2):142-7. doi: 10.1016/j.jamda.2015.08.019. Epub 2015 Oct 9.

Interpretation of mushroom as a common therapeutic agent for Alzheimer's disease and cardiovascular diseases

Rahman MA, Abdullah N, Aminudin N.

Crit Rev Biotechnol. 2016 Dec;36(6):1131-1142. doi: 10.3109/07388551.2015.1100585. Epub 2015 Oct 30.

Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease

Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G.

Neurochem Int. 2016 May;95:63-74. doi: 10.1016/j.neuint.2015.10.011. Epub 2015 Oct 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias